The effects of consumption of Lactobacillus Casei on diabetes control

The effects of consumption of Lactobacillus Casei on glycemic factors, and serum sirtuin1 and fetuin-A levels in type 2 diabetic patients: A controlled clinical trial.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201607034105N17

Enrollment

Registered

2016-08-14

Start date

2016-09-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mallitus. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Placebo capsules Patients in control group will receive placebo capsules daily for two months. Intervention 2: Probiotic Capsules Containing Lactobacillus Casei Patients in interventio

Placebo

Treatment - Drugs

Placebo capsules Patients in control group will receive placebo capsules daily for two months.

Probiotic Capsules Containing Lactobacillus Casei Patients in intervention group will receive one capsule containing 108cfu Lactobacillus Casei daily for two months. Capsules should be taken with

Eligibility

Sex/Gender

All

Age

65 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with diabetes for more than a year of developing diabetes and over 6 months pass the use of glucose lowering drugs ; Age 30 to 50 years. Exclusion criteria: Insulin injections; BMI> 35 Kg / m2; smoking; breastfeeding and pregnancy; menopause; using antibiotics and anti-inflammatory drugs within a month before and during the intervention; chronic digestive problems, and acute gastrointestinal problems within a month before and during the intervention; infectious and inflammatory diseases; Get any supplements.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting Blood Sugar. Timepoint: befor intervention and after 2 monthes intervention. Method of measurement: Spectrophotometry.;HbA1c. Timepoint: befor intervention and after 2 monthes intervention. Method of measurement: Column chromatography.;Insulin Resistance. Timepoint: befor intervention and after 2 monthes intervention. Method of measurement: homeostasis model (HOMA-IR).;Serum Fetuin-A. Timepoint: befor intervention and after 2 monthes intervention. Method of measurement: ELISA technique.;Serum sirtuin1. Timepoint: befor intervention and after 2 monthes intervention. Method of measurement: ELISA technique.	—

Measure

Time frame

Fasting Blood Sugar. Timepoint: befor intervention and after 2 monthes intervention. Method of measurement: Spectrophotometry.;HbA1c. Timepoint: befor intervention and after 2 monthes intervention. Method of measurement: Column chromatography.;Insulin Resistance. Timepoint: befor intervention and after 2 monthes intervention. Method of measurement: homeostasis model (HOMA-IR).;Serum Fetuin-A. Timepoint: befor intervention and after 2 monthes intervention. Method of measurement: ELISA technique.;Serum sirtuin1. Timepoint: befor intervention and after 2 monthes intervention. Method of measurement: ELISA technique.

—

Secondary

Measure	Time frame
Height and Weight. Timepoint: Before Intervention and After2 Monthes Intervention. Method of measurement: Digital scale and stadiometer.;Food Intake. Timepoint: Before Intervention, Middle of the Intervention, and After Intervention. Method of measurement: 24-hour dietary recalls questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLeila Khalili

Tabriz University of Medical Sciences

leylakhalili1990@gmail.com+98 41 3335 7581

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026